Clinic
TH Healthcare, LTD
TH Healthcare, LTD was paid $12.77M by Medicaid between Sep 2020 and Nov 2024, across 68 billing codes. Its largest line is 99284, emergency room visit (serious) — 38% of everything it billed.
33Billing provider infoTH HEALTHCARE, LTD
NACOGDOCHES, TX 75965
NACOGDOCHES, TX 75965
33aNPI1700885076assigned 07/19/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$12.77M
24GClaims75,426
24DCodes billed68
24AFirst – last monthSep 2020 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#37 of 320
Median peer was paid$205K
This provider vs. median62×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 962 | $145K | |
| 2021 | 18,326 | $1.75M | |
| 2022 | 23,632 | $2.77M | |
| 2023 | 23,269 | $6.10M | |
| 2024incomplete | 9,237 | $2.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 8,969 | 8,534 | $4.80M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 12,831 | 12,364 | $3.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 3,277 | 3,000 | $2.10M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 7.8% | 5,884 | 5,665 | $1.00M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.2% | 3,448 | 3,355 | $277K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 2,116 | 1,990 | $130K |
| 80053 | Comprehensive metabolic panel | <1% | 7,145 | 6,505 | $116K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,977 | 7,148 | $85K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 684 | 649 | $69K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,017 | 918 | $57K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,911 | 2,772 | $51K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 25 | 22 | $46K |
56 more codes
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 647 | $40K |
| 87807 | <1% | 1,147 | $38K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 293 | $34K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,010 | $30K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 797 | $25K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,458 | $18K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 59 | $15K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 254 | $14K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 290 | $14K |
| 86738 | <1% | 460 | $13K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 53 | $11K |
| 81001 | <1% | 1,899 | $9K | |
| 87430 | <1% | 1,826 | $8K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 218 | $7K |
| 59025 | Fetal non-stress test | <1% | 50 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 54 | $6K |
| 81003 | <1% | 921 | $5K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 18 | $3K |
| 84484 | <1% | 734 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 364 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,037 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 388 | $2K |
| 31231 | <1% | 13 | $2K | |
| 81025 | <1% | 100 | $2K | |
| 30802 | <1% | 17 | $2K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 73 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 204 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 693 | $1K |
| 83735 | <1% | 275 | $1K | |
| 83880 | <1% | 82 | $1K | |
| 87632 | <1% | 14 | $838.64 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 154 | $763.03 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 709 | $750.79 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 180 | $589.98 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 139 | $521.66 |
| 83605 | <1% | 75 | $502.15 | |
| 74018 | <1% | 13 | $479.01 | |
| 83690 | <1% | 64 | $280.68 | |
| 87186 | <1% | 58 | $249.31 | |
| 87077 | <1% | 56 | $218.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 55 | $165.15 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 45 | $143.17 |
| 87040 | <1% | 42 | $129.95 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $123.80 |
| 85379 | <1% | 13 | $107.89 | |
| A9270 | Non-covered item or service | <1% | 884 | $88.28 |
| 87070 | <1% | 13 | $60.27 | |
| 85610 | <1% | 13 | $37.30 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14 | $37.28 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16 | $36.72 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 38 | $12.57 |
| J2704 | Injection, propofol, 10 mg | 0% | 32 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 26 | $0.00 |
| 94664 | 0% | 13 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSLACK, RANDY (CFO)